Response Genetics Company Profile (NASDAQ:RGDX)

About Response Genetics (NASDAQ:RGDX)

Response Genetics logoResponse Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RGDX
  • CUSIP: N/A
  • Web: www.responsegenetics.com/
Average Prices:
  • 50 Day Moving Avg: $0.17
  • 200 Day Moving Avg: $0.34
  • 52 Week Range: $0.01 - $0.85
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.17
  • P/E Growth: 0.000
Profitability:
  • Net Margins: -106.01%
  • Return on Assets: -133.08%
Misc:
  • Average Volume: 286,022 shs.
 
Frequently Asked Questions for Response Genetics (NASDAQ:RGDX)

What is Response Genetics' stock symbol?

Response Genetics trades on the NASDAQ under the ticker symbol "RGDX."

How were Response Genetics' earnings last quarter?

Response Genetics, Inc. (NASDAQ:RGDX) released its earnings results on Tuesday, March, 31st. The company reported ($0.09) earnings per share (EPS) for the quarter. The company earned $4.10 million during the quarter. View Response Genetics' Earnings History.

Who are some of Response Genetics' key competitors?

Who are Response Genetics' key executives?

Response Genetics' management team includes the folowing people:

  • Thomas A. Bologna, Chairman of the Board, Chief Executive Officer
  • Kevin Roy Harris, Chief Financial Officer, Vice President
  • Adanech Getachew, General Counsel
  • Kirk K. Calhoun, Lead Independent Director
  • Michael Serruya, Director
  • Sam Chawla, Independent Director
  • David R Schreiber, Independent Director
  • Richard A. van den Broek, Independent Director

How do I buy Response Genetics stock?

Shares of Response Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Response Genetics' stock price today?

One share of Response Genetics stock can currently be purchased for approximately $0.03.


MarketBeat Community Rating for Response Genetics (NASDAQ RGDX)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  5 (Vote Underperform)
Total Votes:  18
MarketBeat's community ratings are surveys of what our community members think about Response Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Response Genetics (NASDAQ:RGDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Response Genetics (NASDAQ:RGDX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Response Genetics (NASDAQ:RGDX)
Earnings by Quarter for Response Genetics (NASDAQ:RGDX)
Earnings History by Quarter for Response Genetics (NASDAQ RGDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2015Q115($0.10)$3.90 million$3.80 millionViewListenView Earnings Details
3/31/2015Q414($0.09)$4.10 millionViewN/AView Earnings Details
8/14/2014Q214($0.08)$3.90 million$4.30 millionViewN/AView Earnings Details
5/8/2014Q114($0.06)($0.03)$5.50 million$3.90 millionViewN/AView Earnings Details
3/20/2014Q413($0.07)($0.09)$5.30 million$4.80 millionViewN/AView Earnings Details
11/7/2013Q313($0.07)($0.08)$5.40 million$4.10 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.04)($0.11)$5.40 million$5.30 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.04)($0.03)$4.92 million$5.60 millionViewN/AView Earnings Details
11/13/2012Q312($0.07)($0.05)$4.50 million$5.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Response Genetics (NASDAQ:RGDX)
Current Year EPS Consensus Estimate: $-0.190 EPS
Next Year EPS Consensus Estimate: $-0.150 EPS

Dividends

Dividend History for Response Genetics (NASDAQ:RGDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Response Genetics (NASDAQ:RGDX)
Insider Trades by Quarter for Response Genetics (NASDAQ:RGDX)
Insider Trades by Quarter for Response Genetics (NASDAQ:RGDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/23/2013Austin W & Greenhouse Da MarxeMajor ShareholderSell134,991$1.11$149,840.01View SEC Filing  
12/19/2013Austin W & Greenhouse Da MarxeMajor ShareholderSell135,666$1.18$160,085.88View SEC Filing  
12/16/2013Austin W & Greenhouse Da MarxeMajor ShareholderSell353,677$1.17$413,802.09View SEC Filing  
11/27/2012Austin W & Greenhouse Da MarxeMajor ShareholderBuy463,278$1.02$472,543.56View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Response Genetics (NASDAQ:RGDX)
Latest Headlines for Response Genetics (NASDAQ:RGDX)
Source:

Social

Chart

Response Genetics (RGDX) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff